− Announces Planned Appointment of Jeff Poulton
–
− Manmeet S. Soni to Resign After a Transition
Period –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that Jeff Poulton is joining
the Company on July 11, 2019 and has been appointed Executive Vice
President and Chief Financial Officer (CFO), effective August 13,
2019. Jeff will join Alnylam with nearly 25 years of financial,
operational and strategic leadership experience, including serving
as Executive Vice President and CFO of Shire plc. Manmeet S. Soni
has decided to resign to pursue other interests; he will continue
as CFO of Alnylam through August 12, 2019 providing a smooth
transition.
“The Board of Directors and I are sincerely grateful to Manmeet
for his many contributions in support of Alnylam’s global expansion
and commercialization activities over the last couple of years,
where he led the buildout of our global financial and operational
infrastructure and strengthened the Company’s balance sheet with
over $1.5 billion in new equity capital. I’m grateful that Manmeet
will assist in a smooth transition, and we wish him well in his
next endeavor,” said John Maraganore, Ph.D., Chief Executive
Officer of Alnylam. “Jeff brings a wealth of experience to Alnylam
that is ideal at this exciting point in our Company’s ongoing
growth. He is a seasoned leader with a proven track record and I
look forward to partnering with him to drive our transition toward
a global, multi-product and self-sustainable company with a deep
clinical pipeline and robust product engine for future
innovation.”
“I’ve thoroughly enjoyed my time as part of the Alnylam team and
am proud of the many contributions made to launch the Company as a
commercial enterprise and support its global expansion across
multiple geographies,” said Manmeet S. Soni, Chief Financial
Officer of Alnylam. “I am confident that the foundation created
over the past few years will serve the Company well for many years
to come, and that Alnylam’s emerging transition toward a
sustainable business is very much in hand. I look forward to
working with Jeff during the transition period.”
“The opportunity to join a company like Alnylam that lives at
the leading edge of RNAi science, clinical development and patient
care by leveraging its powerful product engine is unmatched,” said
Jeff Poulton. “With a strong commercial launch of ONPATTRO
underway, a New Drug Application and Marketing Authorization
Application for a second investigational RNAi therapeutic having
been recently filed with the FDA and EMA, and a robust pipeline of
opportunities, including several now in Phase 3, I look forward to
leveraging my experience toward bringing innovative medicines to
patients around the globe.”
Mr. Poulton was most recently Chief Financial Officer of Indigo
Ag, Inc., a company dedicated to harnessing nature to help farmers
sustainably feed the planet. Prior to that Mr. Poulton was Chief
Financial officer of Shire plc, and member of Shire’s Executive
Committee and Board of Directors. As CFO of Shire, he had
responsibility for all aspects of the finance organization
including SEC reporting, Treasury, Tax, Internal Audit, Financial
Planning & Analysis, Investor Relations, and Procurement. Prior
to his CFO role at Shire he held a variety of financial roles and
also served in a general management capacity while leading Shire’s
rare disease commercial operations in North America, Latin America,
and Asia Pacific.
Prior to his fifteen-year tenure at Shire, Jeff led corporate
finance and business development initiatives in both the energy and
materials manufacturing sectors, in financial leadership positions
at Cinergy Corp and PPG industries. He also served as a U.S. Navy
Commissioned Officer.
Mr. Poulton holds a B.A. in Economics from Duke University and
an MBA in Finance from the Kelly School of Business at Indiana
University. He is a member of the Board of Directors of EIP
Pharmaceuticals.
About Alnylam Alnylam (Nasdaq: ALNY) is leading the
translation of RNA interference (RNAi) into a whole new class of
innovative medicines with the potential to transform the lives of
people afflicted with rare genetic, cardio-metabolic, hepatic
infectious, and central nervous system (CNS)/ocular diseases. Based
on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach for the treatment of a wide
range of severe and debilitating diseases. Founded in 2002, Alnylam
is delivering on a bold vision to turn scientific possibility into
reality, with a robust discovery platform. Alnylam’s first approved
RNAi therapeutic is ONPATTRO® (patisiran) available in the U.S., EU
and Japan. Alnylam has a deep pipeline of investigational
medicines, including five product candidates that are in late-stage
development. Looking forward, Alnylam will continue to execute on
its "Alnylam 2020" strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable
pipeline of RNAi-based medicines to address the needs of patients
who have limited or inadequate treatment options. Alnylam employs
over 1,200 people worldwide and is headquartered in Cambridge, MA.
For more information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at @Alnylam or
on LinkedIn.
Alnylam Forward Looking Statements Various statements in
this release concerning Alnylam's future expectations, plans and
prospects, including, without limitation, Alnylam's expectations
regarding growth, global expansion, the productivity of its product
engine, the transition toward becoming a multi-product,
self-sustainable company with a deep pipeline, and its “Alnylam
2020” guidance for the advancement and commercialization of RNAi
therapeutics, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results and future plans may
differ materially from those indicated by these forward-looking
statements as a result of various important risks, uncertainties
and other factors, including, without limitation, Alnylam's ability
to discover and develop novel drug candidates and delivery
approaches, successfully demonstrate the efficacy and safety of its
product candidates, the pre-clinical and clinical results for its
product candidates, which may not be replicated or continue to
occur in other subjects or in additional studies or otherwise
support further development of product candidates for a specified
indication or at all, actions or advice of regulatory agencies,
which may affect the design, initiation, timing, continuation
and/or progress of clinical trials or result in the need for
additional pre-clinical and/or clinical testing, delays,
interruptions or failures in the manufacture and supply of its
product candidates, obtaining, maintaining and protecting
intellectual property, Alnylam's ability to enforce its
intellectual property rights against third parties and defend its
patent portfolio against challenges from third parties, obtaining
and maintaining regulatory approval, pricing and reimbursement for
products, progress in establishing a commercial and ex-United
States infrastructure, successfully launching, marketing and
selling its approved products globally, Alnylam’s ability to
successfully expand the indication for ONPATTRO in the future,
competition from others using technology similar to Alnylam's and
others developing products for similar uses, Alnylam's ability to
manage its growth and operating expenses, obtain additional funding
to support its business activities, and establish and maintain
strategic business alliances and new business initiatives,
Alnylam's dependence on third parties for development, manufacture
and distribution of products, the outcome of litigation, the risk
of government investigations, and unexpected expenditures, as well
as those risks more fully discussed in the “Risk Factors” filed
with Alnylam's most recent Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission (SEC) and in other filings
that Alnylam makes with the SEC. In addition, any forward-looking
statements represent Alnylam's views only as of today and should
not be relied upon as representing its views as of any subsequent
date. Alnylam explicitly disclaims any obligation, except to the
extent required by law, to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190711005101/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340
Josh Brodsky (Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024